Get latest articles and stories on Latest News at LatestLY. Biocon on Tuesday said its unit Biocon Biologics has completed the multi-billion dollar acquisition of the global biosimilars business of its partner Viatris Inc. Latest News | Biocon Biologics Completes Acquisition of Viatris Global Biosimilars Biz.
Share this article
Share this article
PITTSBURGH and BENGALURU, India, July 28, 2021 /PRNewswire/ Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) today announced that the U.S. Food and Drug Administration (FDA) has approved Semglee
® (insulin glargine-yfgn) injection as the first interchangeable biosimilar product under the 351(k) regulatory pathway.
Biocon Biologics
Viatris CEO Michael Goettler commented: We are extremely proud to achieve the industry s first approval of an interchangeable biosimilar product in the U.S., which will help broaden access to this important diabetes medicine for patients, physicians, payers and providers. This is yet another important milestone for our company that not only continues to underscore the strength of our internal scientific capabilities, but also supports our belief in the promising future of our company as we continue to work to identify innovative ways to increase access to complex treatments f